{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:13:21Z","timestamp":1794453201235,"version":"4.9.1"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T00:00:00Z","timestamp":1645920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006529","name":"Race and Difference Initiative, Emory University","doi-asserted-by":"publisher","award":["29 PFE \/ 30.12.2021"],"award-info":[{"award-number":["29 PFE \/ 30.12.2021"]}],"id":[{"id":"10.13039\/100006529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.biopha.2022.112772","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T23:44:56Z","timestamp":1646091896000},"page":"112772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy"],"prefix":"10.1016","volume":"148","author":[{"given":"Elena Emilia","family":"Babes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Bustea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Abdel-Daim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia Cristina","family":"Nechifor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Stoicescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Mihaela","family":"Brisc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Moisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gitea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Carina","family":"Iovanovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa Florina","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia Mirela","family":"Tit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Gabriela","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"64","key":"10.1016\/j.biopha.2022.112772_bib1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American heart association task force on practice guidelines","volume":"2014","author":"Amsterdam","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"10.1016\/j.biopha.2022.112772_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.biopha.2022.112772_bib4","first-page":"1389","article-title":"Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study","volume":"322","author":"Roper","year":"2001","journal-title":"BMJ Clin. Res. Ed."},{"key":"10.1016\/j.biopha.2022.112772_bib5","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.1038\/s41598-021-88593-x","article-title":"Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112772_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2337\/diacare.13.11.1169","article-title":"Diabetic Cardiomyopathy","volume":"13","author":"Fein","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.CIR.102.9.1014","article-title":"Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry","volume":"102","author":"Malmberg","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib8","doi-asserted-by":"crossref","first-page":"41533","DOI":"10.1007\/s11356-021-14675-y","article-title":"Uncurtaining the pivotal role of ABC transporters in diabetes mellitus","volume":"28","author":"Behl","year":"2021","journal-title":"Environ. Sci. Pollut. Res Int."},{"key":"10.1016\/j.biopha.2022.112772_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1479164119845612","article-title":"Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome","volume":"16","author":"Avogaro","year":"2019","journal-title":"Diab Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2022.112772_bib11","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/jama.290.14.1884","article-title":"Lifetime risk for diabetes mellitus in the United States","volume":"290","author":"Narayan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.112772_bib12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1161\/01.CIR.0000089189.70578.E2","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II","volume":"108","author":"L\u00fcscher","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archinte.164.13.1457","article-title":"Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events","volume":"164","author":"Franklin","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00125-004-1438-z","article-title":"Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys","volume":"47","author":"Py\u00f6r\u00e4l\u00e4","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2022.112772_bib15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/euhj.2002.3193","article-title":"A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS)","volume":"23","author":"Hasdai","year":"2002","journal-title":"Eur. Heart J."},{"issue":"43","key":"10.1016\/j.biopha.2022.112772_bib16","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.2337\/dc20-0059","article-title":"Newly discovered abnormal glucose tolerance in patients with acute myocardial infarction and cardiovascular outcomes: a meta-analysis","author":"Laichuthai","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib17","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.292.20.2495","article-title":"Trends in cardiovascular complications of diabetes","volume":"292","author":"Fox","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2022.112772_bib18","series-title":"Diagnostics","first-page":"10","article-title":"Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors","author":"Vesa","year":"2020"},{"key":"10.1016\/j.biopha.2022.112772_bib19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/archinte.161.14.1717","article-title":"The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up","volume":"161","author":"Hu","year":"2001","journal-title":"Arch. Intern Med."},{"key":"10.1016\/j.biopha.2022.112772_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12872-017-0482-9","article-title":"Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review","volume":"17","author":"Johansson","year":"2017","journal-title":"BMC Cardiovasc Disord."},{"key":"10.1016\/j.biopha.2022.112772_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.11.003","article-title":"Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction","volume":"47","author":"Schmitt","year":"2021","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2022.112772_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1253\/circj.CJ-08-1102","article-title":"Endothelial function and oxidative stress in cardiovascular diseases","volume":"73","author":"Higashi","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.biopha.2022.112772_bib24","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3390\/antiox10081306","article-title":"Pathophysiological association between diabetes mellitus and endothelial dysfunction","volume":"10","author":"Maruhashi","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2022.112772_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2337\/diacare.25.6.1055","article-title":"Advanced glycation end products and endothelial dysfunction in type 2 diabetes","volume":"25","author":"Tan","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib26","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.37358\/RC.19.9.7497","article-title":"Statistical analysis of the relationship between antioxidant activity and the structure of flavonoid compounds","volume":"70","author":"Glevitzky","year":"2019","journal-title":"Rev. Chim."},{"key":"10.1016\/j.biopha.2022.112772_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2022.112772_bib28","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1046\/j.1523-1755.2000.00331.x","article-title":"Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study","volume":"58","author":"Festa","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.biopha.2022.112772_bib29","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1161\/01.CIR.0000037282.92395.AE","article-title":"Diabetic macrovascular disease: the glucose paradox?","volume":"106","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3132\/dvdr.2004.003","article-title":"Acute coronary syndromes and diabetes mellitus","volume":"1","author":"Trichon","year":"2004","journal-title":"Diab Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2022.112772_bib31","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2022.112772_bib32","series-title":"Diagnostics","first-page":"11","article-title":"Value of hematological and coagulation parameters as prognostic factors in acute coronary syndromes","author":"Babes","year":"2021"},{"key":"10.1016\/j.biopha.2022.112772_bib33","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2337\/diacare.24.8.1476","article-title":"Platelet dysfunction in type 2 diabetes","volume":"24","author":"Vinik","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jcem.87.1.8175","article-title":"Impact of diabetes-associated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells","volume":"87","author":"Ren","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2022.112772_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","article-title":"Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs","volume":"16","author":"Patti","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1056-8727(00)00132-X","article-title":"Diabetes mellitus: a hypercoagulable state","volume":"15","author":"Carr","year":"2001","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.biopha.2022.112772_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110714","article-title":"Pleotropic effects of polyphenols in cardiovascular system","volume":"130","author":"Behl","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.112772_bib38","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0735-1097(01)01183-4","article-title":"New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study","volume":"37","author":"Ledru","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0735-1097(02)02065-X","article-title":"Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study","volume":"40","author":"Goraya","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib40","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0195-668X(03)00111-8","article-title":"Clinical studies on coronary revascularization in patients with type 2 diabetes","volume":"24","author":"Mak","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diacare.2.2.120","article-title":"Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study","volume":"2","author":"Kannel","year":"1979","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib42","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2337\/diacare.23.7.962","article-title":"Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies","volume":"23","author":"Lee","year":"2000","journal-title":"Diabetes Care"},{"issue":"39","key":"10.1016\/j.biopha.2022.112772_bib43","first-page":"119","volume":"2018","author":"Ibanez","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MCA.0b013e32832e5c4c","article-title":"Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction","volume":"20","author":"Rasoul","year":"2009","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.biopha.2022.112772_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2009.03.042","article-title":"Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors","volume":"207","author":"De Luca","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2022.112772_bib46","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.amjcard.2007.01.044","article-title":"Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era","volume":"99","author":"Ishihara","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ahj.2007.10.010","article-title":"Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treated with primary percutaneous intervention among patients without previously known diabetes mellitus","volume":"155","author":"Porter","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib48","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1161\/CIRCULATIONAHA.105.535732","article-title":"Implications and treatment of acute hyperglycemia in the setting of acute myocardial infarction","volume":"115","author":"Zarich","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(99)08415-9","article-title":"Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview","volume":"355","author":"Capes","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112772_bib50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-8703(97)70222-9","article-title":"Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial","volume":"133","author":"Behar","year":"1997","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-8703(95)90235-X","article-title":"Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: a statewide study. Myocardial infarction data acquisition system study group","volume":"130","author":"Abbud","year":"1995","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib52","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/euhj.1999.1530","article-title":"Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE study group. Trandolapril cardiac evaluation","volume":"20","author":"Melchior","year":"1999","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib53","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1161\/01.CIR.99.20.2626","volume":"99","author":"Malmberg","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib54","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2337\/diacare.24.8.1422","article-title":"Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction","volume":"24","author":"Mukamal","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib55","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ehj.2004.04.001","article-title":"Long-term, cause-specific mortality after myocardial infarction in diabetes","volume":"25","author":"Timmer","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2796.2000.00007.x","article-title":"Diabetes mellitus is a strong negative prognostic factor in patients with myocardial infarction treated with thrombolytic therapy","volume":"248","author":"Strandberg","year":"2000","journal-title":"J. Intern Med."},{"key":"10.1016\/j.biopha.2022.112772_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/14017439950141803","article-title":"In-hospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era","volume":"33","author":"Kjaergaard","year":"1999","journal-title":"Scand. Cardiovasc J."},{"key":"10.1016\/j.biopha.2022.112772_bib58","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2337\/diacare.22.11.1827","article-title":"Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients","volume":"22","author":"Norhammar","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib59","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0735-1097(02)02483-X","article-title":"Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?","volume":"40","author":"Wahab","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.amjcard.2007.08.034","article-title":"Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study)","volume":"101","author":"Pinto","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2006.08.107","article-title":"Cornel, J.; Umans, V. The impact of admission plasma glucose on long-term mortality after STEMI and NSTEMI myocardial infarction","volume":"121","author":"Dirkali","year":"2007","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ahj.2009.10.004","article-title":"Admission and fasting plasma glucose for estimating risk of death of diabetic and nondiabetic patients with acute coronary syndrome: nonlinearity of hazard ratios and time-dependent comparison","volume":"158","author":"Cid-Alvarez","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib63","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2022.112772_bib64","doi-asserted-by":"crossref","first-page":"1780683","DOI":"10.1155\/2018\/1780683","article-title":"The impact of type 2 diabetes mellitus on long-term prognosis in patients of different ages with myocardial infarction","volume":"2018","author":"Afanasiev","year":"2018","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.biopha.2022.112772_bib65","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/dom.12827","article-title":"Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era","volume":"19","author":"Gholap","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2022.112772_bib66","first-page":"298","article-title":"Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI","volume":"96","author":"Chandrasekhar","year":"2020","journal-title":"Catheter Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib67","doi-asserted-by":"crossref","first-page":"m2297","DOI":"10.1136\/bmj.m2297","article-title":"Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis","volume":"370","author":"Cai","year":"2020","journal-title":"Bmj"},{"key":"10.1016\/j.biopha.2022.112772_bib68","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.amjcard.2011.11.046","article-title":"Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI)","volume":"109","author":"Brener","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib69","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2004.12.050","article-title":"Myocardial Infarction Study Group: Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction","volume":"45","author":"Timmer","year":"2005","journal-title":"J. AM Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib70","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.amjcard.2007.02.080","article-title":"Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial)","volume":"100","author":"Marso","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib71","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2005.01.088","article-title":"Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus","volume":"95","author":"Timmer","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib72","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2004.10.054","article-title":"Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction","volume":"45","author":"Prasad","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(02)02626-8","article-title":"Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction","volume":"41","author":"Iwakura","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib74","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-019-0946-6","article-title":"Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61","volume":"18","author":"Winzap","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.biopha.2022.112772_bib75","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12933-020-01173-7","article-title":"Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation","volume":"19","author":"Ishihara","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.biopha.2022.112772_bib76","first-page":"198","article-title":"Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes","volume":"3","author":"Lettino","year":"2017","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"key":"10.1016\/j.biopha.2022.112772_bib77","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/HJR.0b013e3282f335d0","article-title":"Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart","volume":"15","author":"Anselmino","year":"2008","journal-title":"Eur. J. Cardiovasc Prev. Rehabil."},{"key":"10.1016\/j.biopha.2022.112772_bib78","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/01.CIR.0000048897.03553.E4","article-title":"Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial","volume":"107","author":"Sobel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","article-title":"Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients","volume":"343","author":"Trialists","year":"1994","journal-title":"lancet"},{"key":"10.1016\/j.biopha.2022.112772_bib80","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.1991.03470040092028","article-title":"Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators","volume":"266","author":"Pfeffer","year":"1991","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2022.112772_bib81","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1161\/01.CIR.97.12.1150","article-title":"Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2","volume":"97","author":"Barron","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib82","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1262-3636(07)70033-2","article-title":"Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey","volume":"29","author":"Vaur","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2022.112772_bib83","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0735-1097(97)00394-X","volume":"30","author":"Mahaffey","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib84","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(02)07595-5","article-title":"Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE)","volume":"359","author":"Eagle","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112772_bib85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0735-1097(97)00118-6","article-title":"Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction","volume":"30","author":"Mak","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib86","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0002-8703(02)00136-9","article-title":"Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy","volume":"144","author":"Angeja","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib87","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jacc.2015.10.005","volume":"67","author":"Levine","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mhj.2003.40","article-title":"Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials","volume":"145","author":"Grines","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib89","first-page":"16","article-title":"Coronary revascularization in diabetic patients: current state of evidence","volume":"16","author":"Singh","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib90","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0735-1097(01)01477-2","article-title":"Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction","volume":"38","author":"Ishihara","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib91","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1177\/0300060516675504","article-title":"Coronary microvascular dysfunction in diabetes mellitus","volume":"45","author":"Kibel","year":"2017","journal-title":"J. Int Med Res."},{"key":"10.1016\/j.biopha.2022.112772_bib92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/cs0990169","article-title":"The impairment in endothelial function induced by non-esterified fatty acids can be reversed by insulin","volume":"99","author":"Lind","year":"2000","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2022.112772_bib93","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0735-1097(02)02972-8","article-title":"Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus","volume":"41","author":"Gresele","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib94","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1056-8727(00)00068-4","article-title":"Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia","volume":"14","author":"Hokama","year":"2000","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.biopha.2022.112772_bib95","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1161\/01.CIR.0000134278.50359.CB","article-title":"Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion","volume":"109","author":"Gibson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib96","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1161\/01.CIR.0000014683.52177.B5","article-title":"Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction","volume":"105","author":"Gibson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib97","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000346386","article-title":"Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction","volume":"124","author":"Wang","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.biopha.2022.112772_bib98","first-page":"576","article-title":"Simple clinical risk score for no-reflow prediction in patients undergoing primary percutaneous coronary intervention with acute STEMI","volume":"31","author":"Dogan","year":"2015","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.biopha.2022.112772_bib99","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.3390\/jcm9092956","article-title":"No-Reflow after PPCI\u2014a predictor of short-term outcomes in STEMI patients","volume":"9","author":"Pantea-Ro\u0219an","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amjcard.2005.03.040","article-title":"Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus","volume":"96","author":"Cao","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib101","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/archinte.164.9.982","article-title":"Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus","volume":"164","author":"Stranders","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib102","article-title":"Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction","volume":"99","author":"Yang","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.biopha.2022.112772_bib103","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ehj.2003.12.014","article-title":"Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction","volume":"25","author":"Zeller","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108959","article-title":"Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? pathophysiology and clinical evidence","volume":"178","author":"Caturano","year":"2021","journal-title":"Diabetes Res. Clin. Pr."},{"key":"10.1016\/j.biopha.2022.112772_bib105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0735-1097(95)00126-K","article-title":"Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year","volume":"26","author":"Malmberg","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib106","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/eurheartj\/ehi199","article-title":"Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity","volume":"26","author":"Malmberg","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib107","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/diacare.29.04.06.dc05-1894","article-title":"The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction","volume":"29","author":"Cheung","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.112772_bib108","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jama.293.4.437","article-title":"CREATE-ECLA Trial Group Investigators, Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial","volume":"293","author":"Mehta","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.112772_bib109","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.15829\/1560-4071-2021-4418","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"26","author":"Collet","year":"2021","journal-title":"Russ. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib111","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2012.02.059","article-title":"An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials","volume":"60","author":"O\u2019Donoghue","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib112","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCINTERVENTIONS.111.963512","article-title":"Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass angioplasty revascularization investigation 2 Diabetes (BARI 2D","volume":"5","author":"Schwartz","year":"2012","journal-title":"Circ. Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)02427-2","article-title":"Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease","volume":"356","author":"Wallentin","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112772_bib114","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2003.08.050","article-title":"Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization","volume":"43","author":"Norhammar","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib115","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib116","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(17)31490-3","article-title":"Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials","volume":"390","author":"Jobs","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112772_bib117","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","article-title":"PCI strategies in patients with acute myocardial infarction and cardiogenic shock","volume":"377","author":"Thiele","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib118","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/hc4801.100029","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes","volume":"104","author":"Roffi","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib119","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jama.293.14.1759","article-title":"Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials","volume":"293","author":"De Luca","year":"2005","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2022.112772_bib120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.292.3.362","article-title":"Early vs late administration of glycoprotein IIb\/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis","volume":"292","author":"Montalescot","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2022.112772_bib121","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib122","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/eurheartj\/ehl472","article-title":"Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients\u2019 data with long-term follow-up","volume":"28","author":"Montalescot","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2004.08.054","article-title":"Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)","volume":"95","author":"Stuckey","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib124","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1161\/01.CIR.100.25.2477","article-title":"Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb\/IIIa inhibitor for stenting trial) diabetic substudy","volume":"100","author":"Marso","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib125","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1161\/01.CIR.0000018123.02672.C7","article-title":"Impact of different platelet glycoprotein IIb\/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up","volume":"105","author":"Roffi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib126","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0735-1097(99)00650-6","article-title":"Abciximab reduces mortality in diabetics following percutaneous coronary intervention","volume":"35","author":"Bhatt","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib127","first-page":"896","article-title":"Impact of platelet glycoprotein IIb\/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents","volume":"71","author":"Nikolsky","year":"2008","journal-title":"Catheter Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib128","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.31925\/farmacia.2021.5.14","article-title":"Oral antiplatelet therapy in acute coronary syndromes, clinical experience in an emergency hospital with percutaneous coronary intervention facilities","volume":"69","author":"Babes","year":"2021","journal-title":"Farmacia"},{"key":"10.1016\/j.biopha.2022.112772_bib130","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib131","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jcin.2020.07.032","article-title":"Ticagrelor or Prasugrel in patients with acute coronary syndromes and diabetes mellitus","volume":"13","author":"Ndrepepa","year":"2020","journal-title":"JACC Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib132","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","article-title":"Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study","volume":"115","author":"Angiolillo","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib133","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib134","first-page":"186","article-title":"Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial","volume":"8","author":"Korjian","year":"2019","journal-title":"Eur. Heart J. Acute Cardiovasc Care"},{"key":"10.1016\/j.biopha.2022.112772_bib135","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","author":"Oldgren","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib136","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/clc.23514","article-title":"Benefit and risk of adding rivaroxaban in patients with coronary artery disease: a systematic review and meta\u2010analysis","volume":"44","author":"Xie","year":"2021","journal-title":"Clin. Cardiol."},{"issue":"53","key":"10.1016\/j.biopha.2022.112772_bib137","first-page":"34","article-title":"ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"2018","author":"Valgimigli","year":"2017","journal-title":"Eur. J. cardio-Thorac. Surg."},{"key":"10.1016\/j.biopha.2022.112772_bib138","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib139","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FJC.0000000000000856","article-title":"Low-dose ticagrelor in patients with high ischemic risk and previous myocardial infarction: a multicenter prospective real-world observational study","volume":"76","author":"Cesaro","year":"2020","journal-title":"J. Cardiovasc Pharm."},{"key":"10.1016\/j.biopha.2022.112772_bib141","article-title":"ESC Guidelines for the diagnosis and management of chronic coronary syndromesThe Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","author":"Knuuti","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib142","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib143","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5603\/CJ.a2020.0132","article-title":"Prolonged antithrombotic therapy in patients after acute coronary syndrome: a critical appraisal of current European Society of Cardiology guidelines","volume":"27","author":"Kubica","year":"2020","journal-title":"Cardiol. J."},{"key":"10.1016\/j.biopha.2022.112772_bib144","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2021.10.138","article-title":"Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry","volume":"345","author":"Cesaro","year":"2021","journal-title":"Int J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0300-8932(09)70889-9","article-title":"Diabetics and drug-eluting stents in ST segment elevation myocardial infarction: confidence in numbers","volume":"62","author":"Ng","year":"2009","journal-title":"Rev. Esp. De. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib146","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ehj.2003.11.002","article-title":"Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: insights from the RAVEL trial","volume":"25","author":"Abizaid","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib147","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jacc.2004.10.075","article-title":"Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial","volume":"45","author":"Hermiller","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib148","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib149","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1161\/01.CIR.0000129767.45513.71","article-title":"Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy","volume":"109","author":"Moussa","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib150","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/CIRCULATIONAHA.105.562421","article-title":"Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial","volume":"112","author":"Sabat\u00e9","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib151","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1161\/CIRCULATIONAHA.108.820159","article-title":"Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry","volume":"118","author":"Garg","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib152","first-page":"8","article-title":"Efficacy of drug-eluting stents in diabetic patients admitted with ST-elevation myocardial infarctions treated with primary percutaneous coronary intervention","author":"Schmucker","year":"2021","journal-title":"J. Cardiovasc Dev. Dis."},{"key":"10.1016\/j.biopha.2022.112772_bib153","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/eurheartj\/ehp424","article-title":"S.S.s. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"31","author":"Stenestrand","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib154","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJMoa044372","article-title":"ISAR-diabetes Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients","volume":"353","author":"Dibra","year":"2005","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0300-8932(09)70892-9","article-title":"Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials","volume":"62","author":"Iijima","year":"2009","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib156","doi-asserted-by":"crossref","first-page":"a1331","DOI":"10.1136\/bmj.a1331","article-title":"Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis","volume":"337","author":"Stettler","year":"2008","journal-title":"Bmj"},{"key":"10.1016\/j.biopha.2022.112772_bib157","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ahj.2011.07.003","article-title":"A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease","volume":"162","author":"Kufner","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib158","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCINTERVENTIONS.111.964650","article-title":"Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort","volume":"5","author":"Park","year":"2012","journal-title":"Circ. Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib159","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.jacc.2008.03.028","article-title":"Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis","volume":"51","author":"Mahmud","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib160","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.amjcard.2012.07.022","article-title":"Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus-and sirolimus-eluting stents (from the SORT OUT IV trial)","volume":"110","author":"Jensen","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib161","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/CIRCULATIONAHA.110.015453","article-title":"Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial","volume":"124","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112772_bib162","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijcard.2016.12.116","article-title":"Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: a meta-analysis of randomized trials","volume":"230","author":"Bavishi","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib163","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ahj.2012.02.006","article-title":"The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Libert\u00e9 paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions","volume":"163","author":"Grube","year":"2012","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib164","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcin.2012.12.123","article-title":"The \u201cfinal\u201d 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent","volume":"6","author":"Kirtane","year":"2013","journal-title":"JACC Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib165","article-title":"Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial","volume":"8","author":"Iqbal","year":"2015","journal-title":"Circ. Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib166","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcin.2013.04.011","volume":"6","author":"Serruys","year":"2013","journal-title":"JACC Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib167","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jcin.2021.09.028","article-title":"Differential effects of newer-generation ultrathin-strut versus thicker-strut drug-eluting stents in chronic and acute coronary syndromes","volume":"14","author":"Iglesias Juan","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.biopha.2022.112772_bib168","article-title":"Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the sugar trial","author":"Romaguera","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib169","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.4244\/EIJ-D-21-00181","article-title":"Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition","volume":"17","author":"Gragnano","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.biopha.2022.112772_bib170","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s11739-021-02640-z","article-title":"Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome","volume":"16","author":"Cavallari","year":"2021","journal-title":"Intern Emerg. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib171","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0735-1097(00)00823-8","article-title":"Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. The CABG patch trial investigators and coordinators","volume":"36","author":"Whang","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib172","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0735-1097(02)01969-1","article-title":"Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery","volume":"40","author":"Carson","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib173","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0002-9149(94)90399-9","article-title":"Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry)","author":"Barzilay","year":"1994","journal-title":"Am J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib174","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0195-668X(03)00234-3","article-title":"Myonecrosis following isolated coronary artery bypass grafting is common and associated with an increased risk of long-term mortality","volume":"24","author":"Marso","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12933-020-01069-6","article-title":"Type 2 diabetes mellitus increases the mortality risk after acute coronary syndrome treated with coronary artery bypass surgery","volume":"19","author":"Ram","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2022.112772_bib176","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.athoracsur.2010.04.006","article-title":"Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups","volume":"90","author":"Kurlansky","year":"2010","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.biopha.2022.112772_bib177","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1010-7940(02)00470-0","article-title":"Does the use of bilateral internal mammary artery (IMA) grafts provide incremental benefit relative to the use of a single IMA graft? a meta-analysis approach","volume":"22","author":"Rizzoli","year":"2002","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.biopha.2022.112772_bib178","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/j.jacc.2017.10.029","article-title":"Surgical versus percutaneous coronary revascularization in patients with diabetes and acute coronary syndromes","volume":"70","author":"Ramanathan","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib179","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.amjcard.2017.04.038","article-title":"Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome","volume":"120","author":"Chang","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib180","doi-asserted-by":"crossref","first-page":"9c","DOI":"10.1016\/S0002-9149(99)80390-7","article-title":"Bypass Angioplasty Revascularization Investigation (BARI): baseline clinical and angiographic data","volume":"75","author":"Rogers","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib181","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/eurheartj\/ehr213","article-title":"Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and\/or three-vessel disease: 3-year follow-up of the SYNTAX trial","volume":"32","author":"Kappetein","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib182","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/ejcts\/ezt017","article-title":"Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial","volume":"43","author":"Kappetein","year":"2013","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.biopha.2022.112772_bib183","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehu213","article-title":"Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial","volume":"35","author":"Head","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.112772_bib184","article-title":"Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients","volume":"9","author":"Koskinas","year":"2016","journal-title":"Circ. Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib185","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacc.2009.10.014","article-title":"Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial","volume":"55","author":"Kapur","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib186","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jcin.2010.12.004","article-title":"5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials","volume":"4","author":"Onuma","year":"2011","journal-title":"JACC Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib187","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jacc.2012.11.044","article-title":"Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes","volume":"61","author":"Kamalesh","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib188","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","article-title":"Strategies for multivessel revascularization in patients with diabetes","volume":"367","author":"Farkouh","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib189","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa1415447","article-title":"Trial of everolimus-eluting stents or bypass surgery for coronary disease","volume":"372","author":"Park","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112772_bib190","article-title":"Everolimus eluting stents versus coronary artery bypass graft surgery for patients with diabetes mellitus and multivessel disease","volume":"8","author":"Bangalore","year":"2015","journal-title":"Circ. Cardiovasc Inter."},{"key":"10.1016\/j.biopha.2022.112772_bib191","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2213-8587(13)70089-5","article-title":"Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials","volume":"1","author":"Verma","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2022.112772_bib192","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000354","article-title":"Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data","volume":"2","author":"Hakeem","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2022.112772_bib193","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.738620","article-title":"Reassessing revascularization strategies in coronary artery disease and type 2 diabetes mellitus","volume":"8","author":"Liang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2022.112772_bib194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-43681-x","article-title":"Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and\/or left main coronary artery disease","volume":"9","author":"Xin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112772_bib195","first-page":"152","article-title":"Drug-eluting stents versus coronary artery bypass grafting in multivessel disease and left main obstruction: meta-analysis of randomized clinical trials","volume":"31","author":"Andrade","year":"2018","journal-title":"Int. J. Cardiovasc. Sci."},{"key":"10.1016\/j.biopha.2022.112772_bib196","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/clc.23613","article-title":"Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary heart disease and type 2 diabetes mellitus: cumulative meta-analysis","volume":"44","author":"Xie","year":"2021","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.biopha.2022.112772_bib197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-019-0506-y","article-title":"Clinical outcome comparison of percutaneous coronary intervention and bypass surgery in diabetic patients with coronary artery disease: a meta-analysis of randomized controlled trials and observational studies","volume":"11","author":"Zhai","year":"2019","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.biopha.2022.112772_bib198","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019834","article-title":"Ten-year outcomes after drug-eluting stents or bypass surgery for left main coronary disease in patients with and without diabetes mellitus: the PRECOMBAT extended follow-up study","volume":"10","author":"Jeong","year":"2021","journal-title":"J. Am. Heart Assoc."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:32:22Z","timestamp":1781764342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222001603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":198,"alternative-id":["S0753332222001603"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112772","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112772"}}